Literature DB >> 10558966

Nucleoside analogues achieve high concentrations in seminal plasma: relationship between drug concentration and virus burden.

A S Pereira1, A D Kashuba, S A Fiscus, J E Hall, R R Tidwell, L Troiani, J A Dunn, J J Eron, M S Cohen.   

Abstract

Human immunodeficiency virus (HIV) can be transmitted in semen from a man to his sexual partners. Antiretroviral drugs are likely to affect the amount of HIV-1 in semen and perhaps transmission of the virus. The concentrations of zidovudine, lamivudine, and HIV-1 RNA in blood and seminal plasma were measured in 9 HIV-positive men over </=2 years. Median (25th-75th percentiles) zidovudine blood and seminal plasma concentrations were 64.2 (range, 48.4-206.9; n=82) and 292.5 (range, 194.3-438.4; n=79) ng/mL, respectively. Median lamivudine blood and seminal plasma concentrations were 391.3 (range, 175.3-793.8; n=82) and 2701.8 (range, 1460.5-4320.2; n=79) ng/mL, respectively. The concentration of HIV-1 RNA in seminal plasma was monitored as a potential surrogate marker for infectiousness. RNA became undetectable (<400 copies/mL) in the blood and seminal plasma of 8/9 subjects after initiation of therapy and remained undetectable in 6/9 subjects. These data show that zidovudine and lamivudine achieve high concentrations in seminal plasma and significantly reduce HIV-1 RNA. The effects of antiviral therapy on HIV-1 in semen and on the sexual transmission of HIV-1 require further study.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10558966     DOI: 10.1086/315149

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  22 in total

Review 1.  Antiretroviral drug concentrations in semen of HIV-1 infected men.

Authors:  S Taylor; A S Pereira
Journal:  Sex Transm Infect       Date:  2001-02       Impact factor: 3.519

2.  Antiretroviral-drug concentrations in semen.

Authors:  K Gallicano
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

3.  Antiretroviral therapy as HIV prevention: status and prospects.

Authors:  Kenneth H Mayer; Kartik K Venkatesh
Journal:  Am J Public Health       Date:  2010-08-19       Impact factor: 9.308

Review 4.  Pharmacokinetics of antiretrovirals in genital secretions and anatomic sites of HIV transmission: implications for HIV prevention.

Authors:  Christine R Trezza; Angela D M Kashuba
Journal:  Clin Pharmacokinet       Date:  2014-07       Impact factor: 6.447

Review 5.  Antiretroviral Therapy and Alcohol Interactions: X-raying Testicular and Seminal Parameters Under the HAART Era.

Authors:  Oluwatosin O Ogedengbe; Edwin C S Naidu; Onyemaechi O Azu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2018-04       Impact factor: 2.441

6.  Domestic cat model for predicting human nucleoside analogue pharmacokinetics in blood and seminal plasma.

Authors:  H L Jordan; A S Pereira; M S Cohen; A D Kashuba
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

7.  Pharmacokinetic profiles of nevirapine and indinavir in various fractions of seminal plasma.

Authors:  R M van Praag; S Repping; J W de Vries; J M Lange; R M Hoetelmans; J M Prins
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

Review 8.  Treatment to prevent transmission of HIV-1.

Authors:  Myron S Cohen; Cynthia L Gay
Journal:  Clin Infect Dis       Date:  2010-05-15       Impact factor: 9.079

9.  HIV-1-RNA Decay and Dolutegravir Concentrations in Semen of Patients Starting a First Antiretroviral Regimen.

Authors:  Arkaitz Imaz; Javier Martinez-Picado; Jordi Niubó; Angela D M Kashuba; Elena Ferrer; Dan Ouchi; Craig Sykes; Nerea Rozas; Laura Acerete; Jordi Curto; Antonia Vila; Daniel Podzamczer
Journal:  J Infect Dis       Date:  2016-08-30       Impact factor: 5.226

10.  Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients.

Authors:  Caroline Solas; Alain Lafeuillade; Philippe Halfon; Stéphane Chadapaud; Gilles Hittinger; Bruno Lacarelle
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.